Miami Cancer Institute Precision Oncology Symposium, Second Annual - Day 2 Evaluation

Please select one: *

I am in active clinical practice

I am retired

I am a student

Other

Please score your agreement with or assessment of the following questions and statements by rating on a scale of 1 to 5, with 5 representing the highest level of satisfaction or agreement. *

Scoring Key: 5=Strongly Agree 4= Somewhat agree 3=Neither agree nor disagree 2= Somewhat disagree 1=Strongly disagree NA=Not applicable

	5	4	3	2	1	NA
The skills learned in this CME course enhanced my professional competence.	The skills learned in this CME course enhanced my professional competence. - 5	The skills learned in this CME course enhanced my professional competence. - 4	The skills learned in this CME course enhanced my professional competence. - 3	The skills learned in this CME course enhanced my professional competence. - 2	The skills learned in this CME course enhanced my professional competence. - 1	The skills learned in this CME course enhanced my professional competence. - NA
The skills learned in this CME course will be applied in the treatment of my patients	The skills learned in this CME course will be applied in the treatment of my patients - 5	The skills learned in this CME course will be applied in the treatment of my patients - 4	The skills learned in this CME course will be applied in the treatment of my patients - 3	The skills learned in this CME course will be applied in the treatment of my patients - 2	The skills learned in this CME course will be applied in the treatment of my patients - 1	The skills learned in this CME course will be applied in the treatment of my patients - NA

How confident are you in your ability to: *

5 = High level of confidence 4 = Moderately high level of confidence 3 = Average level of confidence 2 = Low level of confidence 1 = No level of confidence Not applicable|Not applicable

	5	4	3	2	1	Not applicable
Properly diagnose and manage solid tumor malignancies.	Properly diagnose and manage solid tumor malignancies. - 5	Properly diagnose and manage solid tumor malignancies. - 4	Properly diagnose and manage solid tumor malignancies. - 3	Properly diagnose and manage solid tumor malignancies. - 2	Properly diagnose and manage solid tumor malignancies. - 1	Properly diagnose and manage solid tumor malignancies. - Not applicable
Provide an update of new molecular and targeted treatments being developed for solid tumors.	Provide an update of new molecular and targeted treatments being developed for solid tumors. - 5	Provide an update of new molecular and targeted treatments being developed for solid tumors. - 4	Provide an update of new molecular and targeted treatments being developed for solid tumors. - 3	Provide an update of new molecular and targeted treatments being developed for solid tumors. - 2	Provide an update of new molecular and targeted treatments being developed for solid tumors. - 1	Provide an update of new molecular and targeted treatments being developed for solid tumors. - Not applicable

How satisfied or dissatisfied were you with the Speaker's effectiveness in addressing the learning objectives? *

Scoring Key: 5=Strongly satisfied 4= Somewhat satisfied 3=Neither satisfied nor dissatisfied 2= Somewhat dissatisfied 1=Strongly dissatisfied

	5	4	3	2	1
The Role of Precision Medicine in the Management of Uterine Cancer - Brian Slomovitz, M.D.	The Role of Precision Medicine in the Management of Uterine Cancer - Brian Slomovitz, M.D. - 5	The Role of Precision Medicine in the Management of Uterine Cancer - Brian Slomovitz, M.D. - 4	The Role of Precision Medicine in the Management of Uterine Cancer - Brian Slomovitz, M.D. - 3	The Role of Precision Medicine in the Management of Uterine Cancer - Brian Slomovitz, M.D. - 2	The Role of Precision Medicine in the Management of Uterine Cancer - Brian Slomovitz, M.D. - 1
Precision Oncology Approaches in Pancreatic and Hepatobiliary Cancers - Rachna Shroff, M.D., M.S.	Precision Oncology Approaches in Pancreatic and Hepatobiliary Cancers - Rachna Shroff, M.D., M.S. - 5	Precision Oncology Approaches in Pancreatic and Hepatobiliary Cancers - Rachna Shroff, M.D., M.S. - 4	Precision Oncology Approaches in Pancreatic and Hepatobiliary Cancers - Rachna Shroff, M.D., M.S. - 3	Precision Oncology Approaches in Pancreatic and Hepatobiliary Cancers - Rachna Shroff, M.D., M.S. - 2	Precision Oncology Approaches in Pancreatic and Hepatobiliary Cancers - Rachna Shroff, M.D., M.S. - 1
The Evolution of Treatment in Advanced Urothelial Carcinoma - Petros Grivas M.D., Ph.D.	The Evolution of Treatment in Advanced Urothelial Carcinoma - Petros Grivas M.D., Ph.D. - 5	The Evolution of Treatment in Advanced Urothelial Carcinoma - Petros Grivas M.D., Ph.D. - 4	The Evolution of Treatment in Advanced Urothelial Carcinoma - Petros Grivas M.D., Ph.D. - 3	The Evolution of Treatment in Advanced Urothelial Carcinoma - Petros Grivas M.D., Ph.D. - 2	The Evolution of Treatment in Advanced Urothelial Carcinoma - Petros Grivas M.D., Ph.D. - 1
Targeted Therapy in ER+/HER2: CDK4/6 Inhibition and Beyond - Joyce O'Shaughnessy, M.D.	Targeted Therapy in ER+/HER2: CDK4/6 Inhibition and Beyond - Joyce O'Shaughnessy, M.D. - 5	Targeted Therapy in ER+/HER2: CDK4/6 Inhibition and Beyond - Joyce O'Shaughnessy, M.D. - 4	Targeted Therapy in ER+/HER2: CDK4/6 Inhibition and Beyond - Joyce O'Shaughnessy, M.D. - 3	Targeted Therapy in ER+/HER2: CDK4/6 Inhibition and Beyond - Joyce O'Shaughnessy, M.D. - 2	Targeted Therapy in ER+/HER2: CDK4/6 Inhibition and Beyond - Joyce O'Shaughnessy, M.D. - 1
HER2 Targeted Treatments: How Low Can You Go? - Ian Krop, M.D., Ph.D.	HER2 Targeted Treatments: How Low Can You Go? - Ian Krop, M.D., Ph.D. - 5	HER2 Targeted Treatments: How Low Can You Go? - Ian Krop, M.D., Ph.D. - 4	HER2 Targeted Treatments: How Low Can You Go? - Ian Krop, M.D., Ph.D. - 3	HER2 Targeted Treatments: How Low Can You Go? - Ian Krop, M.D., Ph.D. - 2	HER2 Targeted Treatments: How Low Can You Go? - Ian Krop, M.D., Ph.D. - 1
ASCO’s Journey of Precision Medicine - Robin Zon, M.D.	ASCO’s Journey of Precision Medicine - Robin Zon, M.D. - 5	ASCO’s Journey of Precision Medicine - Robin Zon, M.D. - 4	ASCO’s Journey of Precision Medicine - Robin Zon, M.D. - 3	ASCO’s Journey of Precision Medicine - Robin Zon, M.D. - 2	ASCO’s Journey of Precision Medicine - Robin Zon, M.D. - 1

Was this course fair, balanced and without commercial bias? *

Yes

No

If you checked "No,” please explain why: *

As a result of my participation in this Symposium, I commit to make the following changes to my clinical practice: *

I will discuss the rationale for new targeted diagnostics and therapeutic strategies for lung cancer, breast cancer, gastrointestinal tumors, genitourinary tumors, head and neck tumors, melanoma, sarcoma and brain tumors.

I will review the role and timing of diagnostic tests, molecular profiling and potential combinations of targeted therapy treatment options.

I will implement the approach of precision oncology in high-grade gliomas..

I will implement the role of biomarkers in urothelial carcinoma.

What, if any, new skills/strategies will you apply in your clinical practice? *

If you do not plan to implement any new skills/strategies in your clinical practice, what is keeping you from doing so? *

Please provide any additional comments or suggestions.

How did you hear about this course? Other...

Name

You are here

Miami Cancer Institute Precision Oncology Symposium, Second Annual - Day 2 Evaluation